Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think AVLN is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.20B
- Enterprise value
- $1.20B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $32.23
- 52-wk low
- $25.05
- Beta
- —
- Shares out
- 44.3M
5-year trend
About AVLN
Business description and risk factors will appear here once AVLN's latest filing is fully ingested.
Earnings tracker
Not enough quarterly history for AVLN yet to draw an earnings tracker.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AVLN — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$25.0M
Insider selling
$0
Net activity
+$25.0M
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AVLN
No institutional holdings on file for AVLN yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once AVLN's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.